Page 5 - Prtk News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Prtk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Prtk Today - Breaking & Trending Today
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) had its target price lowered by BTIG Research from $24.00 to $5.00 in a research note published on Tuesday morning, The Fly reports. PRTK has been the topic of a number of other research reports. HC Wainwright lowered their target price on Paratek Pharmaceuticals from $20.00 to $10.00 in […] ....
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) – HC Wainwright raised their Q2 2023 earnings per share estimates for Paratek Pharmaceuticals in a report issued on Wednesday, May 10th. HC Wainwright analyst E. Arce now anticipates that the specialty pharmaceutical company will earn ($0.30) per share for the quarter, up from their previous forecast of […] ....
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.25 and traded as high as $2.63. Paratek Pharmaceuticals shares last traded at $2.57, with a volume of 367,602 shares. Wall Street Analyst Weigh In PRTK has […] ....
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero purchased 105,137 shares of the company’s stock in a transaction on Monday, March 20th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $147,191.80. Following the purchase, the insider now owns 2,239,770 shares in the […] ....
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero purchased 234,863 shares of the business’s stock in a transaction that occurred on Friday, March 17th. The shares were purchased at an average cost of $1.50 per share, with a total value of $352,294.50. Following the completion of the acquisition, the insider now […] ....